Gliclazide -Teva 60mg 30 tablets — Made in Czech Republic — Free Delivery

Gliclazide-Teva modified release tablets are indicated for type II diabetes mellitus in adults.

Active substance: gliclazide;

1 modified release tablet contains gliclazide 60 mg;

Excipients: lactose, hypromellose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate.

For oral administration.

For adults only.

The daily dose can vary from 30 to 120 mg per day (from 1 to 4 tablets of 30 mg per day or from half to 2 tablets of 60 mg per day).

A 60 mg tablet can be divided into equal portions.

The daily dose should be taken once with breakfast.

Half a tablet or whole tablet (s) should be swallowed whole (do not crush or chew).

If the patient has forgotten to take the tablets, the dose should not be increased the next day.

Like all hypoglycemic agents, Gliclazid-Teva requires an individual dose selection depending on the patient's response to treatment (blood glucose level, glycosylated hemoglobin HbAlc).

Pregnant

Should not be used during pregnancy.

Children

It is not recommended to prescribe.

Drivers

Carefully.

Overdose of sulfonylurea preparations can cause hypoglycemia.

Symptoms of moderate hypoglycemia (without loss of consciousness and without neurological symptoms) must be corrected by taking carbohydrates (sugar), adjusting the dose of a hypoglycemic preparation and / or diet. Close supervision of the patient should be continued until the physician is confident that the patient is safe.

The most common adverse reaction with gliclazide is hypoglycemia. As with other sulfonylurea preparations, taking gliclazide can cause hypoglycemia with irregular meals and especially if meals are skipped. Hypoglycemia can be accompanied by characteristic symptoms such as: headache, severe hunger, nausea, vomiting, fatigue, sleep disturbance, agitation, aggressiveness, decreased concentration and attention, slowing down reactions, depression, confusion, visual and speech impairment, aphasia, tremor , paresis, impaired sensitivity, dizziness, a feeling of powerlessness, loss of self-control, delirium, convulsions, shallow breathing, bradycardia, drowsiness and loss of consciousness, which can lead to coma and death.

Phenylbutazone (for systemic use) enhances the hypoglycemic effect of sulfonylurea preparations (replaces their connection with plasma proteins and / or reduces their excretion). It is advisable to use another anti-inflammatory agent and draw the patient's attention to the need and importance of self-control. If necessary, the dosage is adjusted during and after anti-inflammatory therapy.

Alcohol increases the risk of hypoglycemic reactions (due to inhibition of compensatory reactions), which can lead to hypoglycemic coma. Drinking alcohol and taking medications containing alcohol should be avoided.

The preparation does not require special storage conditions.

Keep out of the reach of children.

Shelf life is 2 years.